



UnitedHealthcare Pharmacy  
Clinical Pharmacy Programs

Program Number	2021 P 3130-2
Program	Step Therapy
Medication	Slynd (drospirenone)
P&T Approval Date	1/2020, 1/2021
Effective Date	4/1/2021; Oxford only: N/A

**1. Background:**

Oral contraceptives are available as either combination estrogen/progesterone-containing contraceptives or as progesterone-only contraceptives. Progesterone-only contraceptives should be used when estrogen-containing contraceptives are contraindicated. Slynd (drospirenone) is a progesterone-only contraceptive indicated for use by females of reproductive potential to prevent pregnancy.

Step Therapy programs are utilized to encourage the use of lower cost alternatives for certain therapeutic classes. This program requires a member to try norethindrone (generic Ortho Micronor) before providing coverage for Slynd.

**2. Coverage Criteria<sup>a</sup>:**

**A. Slynd** will be approved based on **all** the following criteria:

1. History of failure, contraindication, or intolerance to **both** of the following medications:

a. an estrogen/progesterone containing contraceptive [e.g., norgestimate/ethinyl estradiol (generic Ortho Cyclen), Yaz]

-AND-

b. a progesterone-only contraceptive [(i.e. norethindrone (generic Ortho Micronor)]

**Authorization will be issued for 12 months.**

<sup>a</sup> State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply.

**3. Additional Clinical Programs:**

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.

**4. References:**

1. Slynd [package insert]. Florham Park, NJ: Exeltis USA, Inc; May 2019.

Program	Step Therapy – Slynd
<b>Change Control</b>	
1/2020	New program.
1/2021	Annual review. No changes.